ATLANTA, Sept. 5, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel. The Company's fireside chat is scheduled to begin at 2:35 pm ET.
A live webcast can be accessed through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website.
About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.
Contacts:
Artivion | Gilmartin Group LLC | |
Lance A. Berry | Brian Johnston / Laine Morgan | |
Executive Vice President, | Phone: 332-895-3222 | |
Chief Operating Officer & | This email address is being protected from spambots. You need JavaScript enabled to view it.';document.getElementById('cloak4b8f7f2cdab5d38393ba9684e896b26e').innerHTML += ''+addy_text4b8f7f2cdab5d38393ba9684e896b26e+'<\/a>'; | |
Chief Financial Officer | ||
Phone: 770-419-3355 |
| Last Trade: | US$42.61 |
| Daily Change: | 0.53 1.26 |
| Daily Volume: | 225,607 |
| Market Cap: | US$2.010B |
August 07, 2025 February 24, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
